Beinaglutide for weight management in Chinese individuals with overweight or obesity: A phase 3 randomized controlled clinical study

医学 安慰剂 超重 优势比 体质指数 内科学 腰围 肥胖 减肥 置信区间 随机对照试验 不利影响 恶心 胃肠病学 替代医学 病理
作者
Kang Chen,Li Chen,Zhongyan Shan,Guixia Wang,Shen Qu,Guijun Qin,Xuefeng Yu,Weiquan Xin,Tsung‐han Hsieh,Yiming Mu
出处
期刊:Diabetes, Obesity and Metabolism [Wiley]
卷期号:26 (2): 690-698 被引量:12
标识
DOI:10.1111/dom.15360
摘要

Abstract Aim To investigate the efficacy and safety of beinaglutide as an adjunct to lifestyle intervention among non‐diabetic Chinese individuals with overweight or obesity. Methods This multicentre, randomized, double‐blind, placebo‐controlled trial (ChiCTR1900023428) included 427 Chinese adults with a body mass index of 28 kg/m 2 or higher (obesity) or 24‐27.9 kg/m 2 (overweight) with weight‐related complications. Patients were randomized in a 2:1 ratio to receive 0.2 mg of beinaglutide (subcutaneous) thrice daily or placebo for 16 weeks. Co‐primary endpoints were body weight change and the proportion of patients with a weight reduction of 5% or more. Results Mean body weight change from baseline to week 16 was −6.0% and −2.4% in the beinaglutide ( n = 282) and placebo ( n = 138) groups, respectively; the mixed model repeated measures difference was −3.6% (95% confidence interval: −4.6% to −2.6%; P < .0001). At week 16, more beinaglutide‐treated patients achieved a weight reduction of 5% or more (58.2% vs. 25.4% [placebo], odds ratio: 4.4; P < .0001) and of 10% or more (21.3% vs. 5.1% [placebo], odds ratio: 5.5; P < .0001). Beinaglutide also resulted in greater waist circumference reduction (difference: −1.81 cm; P < .01). The weight regain rate 12 weeks after beinaglutide treatment was 0.78%. Nausea (transient and mild‐to‐moderate) was the most common adverse event in the beinaglutide group (49.3% vs. 7.1% [placebo]). More patients receiving beinaglutide discontinued treatment because of adverse events (5.9% vs. 0.7% [placebo]). Pancreatitis or an increased resting heart rate was not observed in the beinaglutide group. Conclusion Beinaglutide combined with lifestyle intervention resulted in significant and clinically meaningful weight reduction with good tolerance in non‐diabetic Chinese individuals with overweight or obesity.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
快乐一江发布了新的文献求助10
刚刚
2秒前
Tianling完成签到,获得积分0
3秒前
好吃鱼完成签到,获得积分10
3秒前
等一个晴天完成签到,获得积分10
6秒前
胡涂涂发布了新的文献求助10
8秒前
研友_VZG7GZ应助小赞采纳,获得10
9秒前
量子星尘发布了新的文献求助10
10秒前
快乐一江完成签到,获得积分10
12秒前
13秒前
18秒前
啊标完成签到,获得积分10
18秒前
18秒前
水溶c100完成签到,获得积分10
19秒前
梨江鱼完成签到,获得积分10
19秒前
LcnTCM完成签到,获得积分10
19秒前
22秒前
maizhenpeng发布了新的文献求助10
23秒前
执着乐双发布了新的文献求助30
25秒前
小赞发布了新的文献求助10
25秒前
29秒前
33秒前
沈静完成签到,获得积分10
33秒前
35秒前
loski发布了新的文献求助10
35秒前
marina完成签到 ,获得积分20
36秒前
39秒前
时尚俊驰发布了新的文献求助10
39秒前
40秒前
文献发布了新的文献求助30
41秒前
44秒前
我嘞个豆完成签到,获得积分10
44秒前
爱笑晓曼发布了新的文献求助10
45秒前
wdy111应助sc采纳,获得20
45秒前
敏感初露发布了新的文献求助10
45秒前
隐形曼青应助机智思真采纳,获得10
48秒前
思源应助时尚俊驰采纳,获得10
48秒前
可爱的函函应助敏感初露采纳,获得10
48秒前
49秒前
爆米花应助橙子采纳,获得10
52秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989378
求助须知:如何正确求助?哪些是违规求助? 3531442
关于积分的说明 11254002
捐赠科研通 3270126
什么是DOI,文献DOI怎么找? 1804887
邀请新用户注册赠送积分活动 882087
科研通“疑难数据库(出版商)”最低求助积分说明 809173